The blood thinner market in the United States was worth over $8 billion in 2012 and is expected to grow to over $15 billion by 2018, according to a June 2013 report by pharmaceutical analysts EvaluatePharma. Xarelto, one of a new type of anti-coagulants that doesn't require individual dosing (unlike category leader Warfarin) is big business for … [Read more...]